Evidence map›Paper›PMID 35182208›Full record

ReviewHerzschrittmachertherapie & Elektrophysiologie2022

[Catheter ablation : Developments and technique selection].

L Yahsaly, J Siebermair, R Wakili

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herzschrittmachertherapie & Elektrophysiologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Pulsed Field Ablation to Treat Atrial Fibrillation: A Review of the Literature.Journal of cardiovascular development and disease · 2022
    Review
  5. [Unstoppable innovations in electrophysiology].Herzschrittmachertherapie & Elektrophysiologie · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

L YahsalyKlinik für Kardiologie und Angiologie, Westdeutsches Herz- und Gefäßzentrum Essen, Hufelandstr. 55, 45122, Essen, Deutschland.
J SiebermairKlinik für Kardiologie und Angiologie, Westdeutsches Herz- und Gefäßzentrum Essen, Hufelandstr. 55, 45122, Essen, Deutschland.
R WakiliKlinik für Kardiologie und Angiologie, Westdeutsches Herz- und Gefäßzentrum Essen, Hufelandstr. 55, 45122, Essen, Deutschland. reza.wakili@uk-essen.de.
West German Heart and Vascular Center Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atrial fibrillation (AF) is the most common arrhythmia and an important risk factor for the occurrence of cardiovascular events. According to current guidelines, rhythm-controlling therapy is recommended only for symptomatic AF. Even in symptomatic AF there is still only a class IIa-recommendation for catheter ablation as initial therapy in paroxysmal AF. Meanwhile, current studies have shown an advantage of the early rhythm control compared to a rate control, as well as a benefit of catheter ablation compared to antiarrhythmic drug (AAD) treatment. The gold standard of catheter ablation for AF therapy is pulmonary vein isolation, which has been mainly radiofrequency-based in the past. However, cryoablation as a first-line therapy of paroxysmal AF is increasingly gaining importance, as the latest studies showed shorter procedure times, lower reintervention rates and improved life quality after cryoablation. Nevertheless, using these standard techniques, the risk of adverse events is still given through collateral damage. The field high-power short duration ablation is currently topic of ongoing AF research, which describes a radiofrequency ablation with higher energy levels, given over shorter duration, with a consecutive lower recurrence rate as well as procedure time. The new ablation techniques also include the pulsed field ablation, which allows ablation through very fast delivery of electrical pulses and causes isolated damage to myocardial cells without collateral damage. This promising technique passed the efficiency and safety testing in preclinical studies. To validate this technique further randomized trials are needed.

Indexed as

Atrial FibrillationCatheter AblationPulmonary VeinsAnti-Arrhythmia AgentsHumansRecurrenceTreatment OutcomeAnti-Arrhythmia AgentsAtrial fibrillationCryoablationHigh-power short duration ablationPulmonary vein isolationPulsed field ablation

Identifiers

PMID35182208
OpenAlexW4213048961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.